NCT03984448 2026-03-18
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
Clinical Trials
13 trialsNCT04799275 2026-03-18
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
National Cancer Institute (NCI)
Phase 2/3 Suspended
NCT05139017 2026-03-10
waveLINE-003
Merck Sharp & Dohme LLC
Phase 2/3 Recruiting
NCT01046825 2025-12-10
Mature B-Cell Lymphoma And Leukemia Study III
St. Jude Children's Research Hospital
Phase 2/3 Active not recruiting
NCT02405676 2025-02-13
BNHL-2015
Children's Cancer Group, China
Phase 2/3 Active not recruiting
NCT03366272 2025-01-28
NIVEAU
Universität des Saarlandes
Phase 2/3 Completed
NCT04061512 2024-05-10
RAINBOW
University College, London
Phase 2/3 Recruiting
NCT00096460 2023-01-05
BMT CTN 0202
Medical College of Wisconsin
Phase 2/3 Terminated
NCT01197560 2019-11-25
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Celgene
Phase 2/3 Completed
NCT00641095 2018-10-31
MCLPIII
University College, London
Phase 2/3 Completed
NCT02871869 2017-07-17
Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma
Xinjiang Medical University
Phase 2/3 Unknown
NCT00147121 2016-09-22
Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203)
Japan Clinical Oncology Group
Phase 2/3 Completed
NCT00045877 2006-02-06
Proleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan Treatments
Chiron Corporation
Phase 2/3 Completed